Merkel cell carcinoma (MCC) is a complex, rare, aggressive disease that requires the expertise of multiple disciplines. As highlighted in the review by Banks et al, 1 we have seen some recent ...

Comparison of operative to monitoring and endocrine therapy for low-risk DCIS (COMET study). NRG Oncology/NSABP B-51/RTOG 1304: Phase III trial to determine if chest wall and regional nodal ...

Limited data are available on survival outcomes after sentinel-lymph-node biopsy alone as compared with lymphadenectomy in cervical cancer. In this multicenter, randomized, noninferiority trial, we ...

Trials evaluating the omission of completion axillary-lymph-node dissection in patients with clinically node-negative breast cancer and sentinel-lymph-node metastases have been compromised by limited ...

Lymph node status in stage I hormone receptor-positive/HER2-negative breast cancer was not a good indicator of genetic-risk scores that would qualify older women for ...

Older women with a very early, non-invasive breast cancer known as ductal carcinoma in situ (DCIS) gain no long-term benefit from undergoing a sentinel lymph node biopsy to see if the cancer has ...

Please provide your email address to receive an email when new articles are posted on . Skipping sentinel lymph node biopsy can be considered for node-negative, HR-positive, HER2-negative early breast ...

Omitting SLNB in older patients with early-stage, HR-positive, HER2-negative breast cancer showed similar safety and efficacy to performing the procedure. The BOOG 13-08 trial demonstrated comparable ...

Skipping sentinel lymph node biopsy (SLNB) in patients with clinically node-negative, hormonal receptor (HR)-positive, HER2-negative early-stage breast cancer did not compromise regional control or ...

Sentinel lymph node (SLN) biopsy for early cervical cancer achieved non-inferiority versus pelvic lymphadenectomy, according to results of a large randomized study from China. Patients assigned to SLN ...